How does the bench-to-bedside process test new treatments developed through basic research?

In the context of translational medicine, the bench-to-bedside process is a bidirectional effort designed to move scientific discoveries from the laboratory into clinical practice efficiently. This process tests new treatments through a rigorous, regulated sequence of clinical trials:1

• Preclinical Testing: Before human trials begin, researchers conduct safety studies in animals to evaluate toxicity and determine appropriate starting doses. Pharmacokinetic investigations are also performed to understand how a drug is absorbed, distributed, metabolized, and excreted.234
• Phase 0 and Phase 1: Exploratory Phase 0 trials may measure specific biological effects in humans, while Phase 1 trials focus on establishing safety and identifying the highest tolerable dose.2
• Phase 2 and Phase 3: Phase 2 trials assess the effectiveness of the treatment in a specific medical condition. If promising, Phase 3 trials use randomized, often double-blind designs to compare the new intervention against standard treatments or a placebo, ensuring results are unbiased.2

This process is governed by strict ethical standards, including the Nuremberg Code and the Declaration of Helsinki, which mandate informed consent to protect participant safety.2